VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.07 Million in Theravance Biopharma, Inc. $TBPH

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 63,000 shares of the biopharmaceutical company's stock, valued at approximately $1,071,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.12% of Theravance Biopharma at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quarry LP purchased a new stake in Theravance Biopharma in the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 781 shares during the period. CIBC Private Wealth Group LLC increased its stake in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 4,662 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the first quarter valued at about $101,000. Hedge funds and other institutional investors own 99.10% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th. HC Wainwright cut Theravance Biopharma from a "buy" rating to a "neutral" rating and boosted their price target for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. JonesTrading downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Monday, June 29th. BTIG Research cut Theravance Biopharma from a "buy" rating to a "neutral" rating in a research report on Monday, June 29th. Finally, Zacks Research cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 7th. Eight analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $19.40.

Insider Transactions at Theravance Biopharma

In related news, major shareholder Eli Samaha sold 273,871 shares of the firm's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 336,697 shares of company stock worth $5,790,093 over the last three months. Corporate insiders own 7.65% of the company's stock.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $17.01 on Monday. The company has a market cap of $883.16 million, a P/E ratio of 16.84 and a beta of 0.25. Theravance Biopharma, Inc. has a one year low of $13.08 and a one year high of $21.03. The firm has a fifty day moving average of $16.95 and a two-hundred day moving average of $16.44.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. As a group, equities analysts predict that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company's work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.